Literature DB >> 29351887

Synthesis and anti-tumor activity of EF24 analogues as IKKβ inhibitors.

Rong Jin1, Qiuxiang Chen2, Song Yao3, Encheng Bai1, Weitao Fu3, Ledan Wang4, Jiabing Wang3, Xiaojing Du1, Tao Wei5, Haineng Xu6, Chengxi Jiang6, Peihong Qiu3, Jianzhang Wu7, Wulan Li8, Guang Liang6.   

Abstract

EF24 is an IKKβ inhibitor (IC50: 72 μM) containing various anti-tumor activities. In this study, a series of EF24 analogs targeting IKKβ were designed and synthesized. Several IKKβ inhibitors with better activities than EF24 were screened out and B3 showed best IKKβ inhibitory (IC50: 6.6 μM). Molecular docking and dynamic simulation experiments further confirmed this inhibitory effect. B3 obviously suppressed the viability of Hela229, A549, SGC-7901 and MGC-803 cells. Then, in SGC-7901 and MGC-803 cells, B3 blocked the NF-κB signal pathway by inhibiting IKKβ phosphorylation, and followed arrested the cell cycle at G2/M phase by suppressing the Cyclin B1 and Cdc2 p34 expression, induced the cell apoptosis by down-regulating Bcl-2 protein and up-regulating cleaved-caspase3. Moreover, B3 significantly reduced tumor growth and suppressed the IKKβ-NF-κB signal pathway in SGC-7901 xenograft model. In total, this study present a potential IKKβ inhibitor as anti-tumor precursor.
Copyright © 2017. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Anti-tumor activity; IKKβ inhibitor; Molecular docking; Synthesis

Mesh:

Substances:

Year:  2017        PMID: 29351887     DOI: 10.1016/j.ejmech.2017.11.077

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  6 in total

1.  CDK1 is up-regulated by temozolomide in an NF-κB dependent manner in glioblastoma.

Authors:  David J Voce; Giovanna M Bernal; Kirk E Cahill; Longtao Wu; Nassir Mansour; Clayton D Crawley; Paige-Ashley S Campbell; Ainhoa Arina; Ralph R Weichselbaum; Bakhtiar Yamini
Journal:  Sci Rep       Date:  2021-03-11       Impact factor: 4.379

2.  NF-κB-Related Metabolic Gene Signature Predicts the Prognosis and Immunotherapy Response in Gastric Cancer.

Authors:  Qiuxiang Chen; Xiaojing Du; Sunkuan Hu; Qingke Huang
Journal:  Biomed Res Int       Date:  2022-01-04       Impact factor: 3.411

3.  Structure-Property Relationships of Dibenzylidenecyclohexanones.

Authors:  Marina V Fomina; Sergey Z Vatsadze; Alexandra Ya Freidzon; Lyudmila G Kuz'mina; Anna A Moiseeva; Roman O Starostin; Vyacheslav N Nuriev; Sergey P Gromov
Journal:  ACS Omega       Date:  2022-03-14

Review 4.  Role of the NFκB-signaling pathway in cancer.

Authors:  Longzheng Xia; Shiming Tan; Yujuan Zhou; Jingguan Lin; Heran Wang; Linda Oyang; Yutong Tian; Lu Liu; Min Su; Hui Wang; Deliang Cao; Qianjin Liao
Journal:  Onco Targets Ther       Date:  2018-04-11       Impact factor: 4.147

5.  Properly Substituted Cyclic Bis-(2-bromobenzylidene) Compounds Behaved as Dual p300/CARM1 Inhibitors and Induced Apoptosis in Cancer Cells.

Authors:  Rossella Fioravanti; Stefano Tomassi; Elisabetta Di Bello; Annalisa Romanelli; Andrea Maria Plateroti; Rosaria Benedetti; Mariarosaria Conte; Ettore Novellino; Lucia Altucci; Sergio Valente; Antonello Mai
Journal:  Molecules       Date:  2020-07-08       Impact factor: 4.411

6.  Anti-Cancer and Ototoxicity Characteristics of the Curcuminoids, CLEFMA and EF24, in Combination with Cisplatin.

Authors:  Jerry D Monroe; Denis Hodzic; Matthew H Millay; Blaine G Patty; Michael E Smith
Journal:  Molecules       Date:  2019-10-29       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.